FAX: (301) 496-4409

E-mail:f 6}

The information in this e-mail and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who is not the original intended recipient. If you
have received this e-mail in error please inform the sender and delete it from your mailbox or any
other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statements made that are the sender's own and not expressly made on
behalf of the NIAID by one of its representatives.

 

 
 

From: Ste McCon (o_O >

Sent: Wednesday, March 18, 2020 5:09 PM

Subject: ATTN: Dr. Fauci / Good ACE bad ACE do battle in lung injury SARS-CoV coronavirus Nicholls $
Peiris M NATURE-Med 9-2005.pdf

"Clearly, the potential therapeutic utility of recombinant ACE2 and angiotensin Il receptor-
inhibitors. [ARB's ?]s—already in clinical use for control of blood pressure—for acute lung
injury resulting from viruses and other causes will be a productive field for investigation. This is
particularly relevant as we prepare to confront a potential avian flu pandemic, [COV/D-19 ?
Jarmed with onlya limited number of therapeutic options."

Regards,

Stephen D. McConnell, BS, MSc-CCP, CIS

Lipidemiologist - Clinical Application Specialist
Medicare-CMS ACO/MSSP/Direct-Contracting Consultant
Medical Science Liaison

Mobile:

Sent from my iPhone

NIH-000431
